While agricultural biotech applications (in Germany, often referred to as “green biotech”) are controversial, demand for so-called “white biotechnology” applications, which aim to make industrial processes more environmentally sound, is expected to increase. Medical applications, referred to as “red biotech,” remain an important area for German pharmaceutical research and product development. Despite the global financing situation, the European biotechnology still shows increasing innovation potential.
Approximately 60% of German biotechnology companies expect to increase their investment in 2010, a drop of 9% in 2009, and half of the companies expect to increase employment.
The best prospects are cardio-, cancer- and neuro-therapeutical products; peptides in the treatment of diabetes; and enzymes used in washing powders and in the textile industry.